SKAN to Miss 2025 Sales and Profit Targets Amid Project Delays

SKAN Group has announced that it will not meet its sales and profit expectations for 2025 due to project delays identified during a recent review. These delays are affecting the group's current financial year earnings. Despite this, SKAN remains optimistic about 2026, expecting a stronger performance driven by positive order intake and a robust backlog.

The company anticipates a decline in net sales for 2025 by a high single-digit percentage compared to 2024. Additionally, the EBITDA margin is projected to stay in the low double-digit range, below the previous guidance of 14% to 16%. Some key projects have been pushed to 2026, affecting December's significant turnover.

Positive developments in order intake, particularly concerning oncology applications and biotech injectables, are expected. This suggests a strong basis for 2026. The medium-term outlook remains favorable, with projected annual net sales growth in the mid-to-upper teens and a gradually increasing EBITDA margin.